This ongoing phase I/II study enrolled untreated EGFR (19 deletion or L858R) NSCLC patients with measurable CNS lesions…The confirmed ORR was 95.8% (23/24), DCR was 100% (24/24), iORR was 91.7% (22/24), iDCR was 100% (24/24), the CNS lesions shrinkage was observed in all patients with a median depth of tumor remission (DepOR) 53.6% (range 11.3%-77.4%)...Aumolertinib plus icotinib as first-line therapy have significant response rate and a manageable safety profile in EGFR-mutant NSCLC patients with CNS metastases.